Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

NCT03567876 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

141

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Venetoclax

Sponsor

Fondazione Italiana Linfomi - ETS

Collaborators

[object Object]